Mitsubishi Heavy Industries Continues Order Intake, Revenue, and Profit Growth in Strong First Half, Raises Full-Year Order Intake Guidance
Eisai’s Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem”
Asahi Kasei and Honda Sign Shareholders’ Agreement to Convert Existing Asahi Kasei Subsidiary into Joint Venture for Production of Lithium-ion Battery Separators in Canada
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
Fujitsu and AMD to begin strategic partnership to develop more sustainable computing infrastructure intended to accelerate open-source AI initiatives
NTT and Toyota Motor Corporation agree to joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD)
Fujitsu and Morinaga Milk Industry jointly develop a simulation system for raw material price fluctuations, speeding up decision-making
ULVAC Launches Technology Center PYEONGTAEK for Next-Gen Semiconductor Manufacturing Equipment in South Korea
